Doctoral Program for World-leading Innovative & Smart Education
Events
【ENDED】Seminar [Aug. 6, 2020 / Application Required] Hiroshima University’s Advanced Science Seminar "Developing a Future Society with Genome Editing" To Be Held
We will hold a total of four seminars with the title "Developing a Future Society with Genome Editing" to introduce our efforts related to genome-editing technology, which is one of Hiroshima University's strengths, and to give easy-to-understand explanations of the potential of genome editing.
The theme of the first round is "Genome-Editing Technology for Understanding and Curing Disease.”
The seminar is free of charge and open to the public. We welcome those interested in the development and industrial use of genome-editing technology.
Date/time: | Thursday, Aug. 6, 2020, 18:30 - 19:30 | |
Venue: | Online seminar (live streaming seminar using the video conference tool Zoom) | |
Language: | Japanese | |
Theme: | Genome-Editing Technology for Understanding and Curing Disease | |
Lecturer: | Tatsuo Miyamoto, Associate Professor, Research Institute for Radiation Biology and Medicine, Hiroshima University | |
Overview: | Genome editing is not only a technology for directly treating genetic abnormalities that cause disease, but also an important technology for elucidating the mechanisms of diseases and developing new drugs. This lecture will feature not only genetic diseases but also the current situation and potential of genome-editing technology, which is expected to help overcome infectious diseases such as COVID-19. | |
Target audience: | Corporate staff, public officials, alumni of Hiroshima University, and citizens who are interested in the theme | |
Fee: | free of charge | |
Application: | Fill out the application form (https://forms.gle/sR6PNczsUVJct9x68)
*Sorry, this entry is only available in Japanese. |
|
Application deadline: | Tuesday, August 4, 2020 *The application form will not be valid after the application deadline. |
|
*Co-sponsored by Program on Open Innovation Platform with Enterprises, Research Institute and Academia: OPERA